🇺🇸·1d agoResearch
NCT07409103: A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
Study type: INTERVENTIONAL. Phase: PHASE2.
Publisher
C
ClinicalTrials.gov
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- ClinicalTrials.gov
- Region
- USA
- Scope
- Research
- Published
- July 20, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Study type: INTERVENTIONAL. Phase: PHASE2.
Source route
Continue on clinicaltrials.gov
Leave the platform to read the original full article on the publisher site.
Source: ClinicalTrials.gov
Scope: Research
Related coverage
More related coverage
CU Anschutz Medical/18h ago
Peptides Explained: What They Do, How They Work and What to Know About Peptide Therapy
Cancer Research UK/19h ago
Data science: making data count with broad consent
UNC Chapel Hill/19h ago
Carolina North will complement University’s vibrant campus
Université de Paris/20h ago